Oncology pharmacy services standards and guidelines are addressed by several regulatory agencies and professional organizations. Standards and guidelines sometimes apply to specific settings of care (as an example, The Joint Commission for hospitals), but the principles pertaining to quality, safety, and effectiveness of cancer care are the concern of Oncology Pharmacy Services in all sites of care.
With the increasing complexity of cancer care, new indications and new drug approvals, emerging biosimilars in oncology, recent advances in immunotherapy, the high cost cancer treatment, and the ever-evolving regulatory and reimbursement landscape, the challenges for Oncology Pharmacy Services are ongoing.
ACCC provides education, resources, and networking opportunities to help cancer programs navigate care coordination issues specific to pharmacy such as reimbursement, distribution, inventory management, communication and training through the Oncology Pharmacy Education Network.
Steps to Success: Implementing Oral Oncolytics
Oral Therapies: A Patient-Centered Approach
Patient-Centered Scheduling: Costs & Benefits of Extending Practice Hours
This special report from ACCC examines the pros and cons of extended infusion suite hours. Included is tool to help practices and programs assess the feasibility of extending hours of care.
Dispensing Pharmacy Patient Education Tool
Physician dispensing is governed by state law and regulated by State Boards of Pharmacy. While some states do not allow physician dispensing, most of the states that allow it require dispensing physicians to alert their patients about other options to fill their prescription(s). In response to this need, ACCC has developed this patient education tool that can be used across care settings.
At the 2018 ASCO Annual Meeting, Oncology Business Review interviewed ACCC member Ivo Abraham, PhD, RN, for an update on biosimilars in oncology. Dr. Abraham is Professor of Pharmacy and Medicine at the University of Arizona in Tucson, Arizona, where he is also affiliated with the Center for Health Outcomes and PharmacoEconomic Research, the Arizona Cancer Center, and the Center for Applied Genomics and Genetic Medicine. Dr. Abraham is a member of the ACCC Immuno-Oncology Institute Executive Committee.
Dr. Abraham shares his perspective on hurdles to adoption of biosimilars in oncology:
Watch more from Dr. Abraham on:
Key features of a biosimilar - via OBR
Biosimilars approved and nearing approval for oncology - via OBR
Biosimilar pricing and reimbursement - via OBR
Access ACCC's comprehensive resource for coding, billing, and reimbursement for oncology drugs.
Access the Database